Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bayer HealthCare receives colorectal cancer approval for Stivarga

Bayer HealthCare receives colorectal cancer approval for Stivarga

2nd September 2013

Bayer HealthCare has received approval from the European Commission for Stivarga, its new therapy for the treatment of colorectal cancer.

The drug has been ratified for use as a treatment for adult patients with metastatic colorectal cancer (mCRC) who have previously been treated with – or are not considered candidates for – available therapies.

Stivarga has already been approved for this indication in the US and Japan after demonstrating its safety and efficacy in the pivotal phase III trial Correct.

There is a significant unmet need for new treatment options for this disease, as patients with early forms of the cancer currently need to undergo surgery, preceded or followed by radiotherapy and/or chemotherapy.

Dr Kemal Malik, member of the Bayer HealthCare executive committee and head of global development, said: "At Bayer, we are committed to developing treatments that can improve the lives of patients and from this data anticipate that Stivarga can positively impact those suffering from mCRC."

This comes after the company also received European Commission approval for Eylea to be used for the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion last week.ADNFCR-8000103-ID-801632146-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.